Join us for invaluable insights on successful commercialization strategies in the U.S. for cell and gene therapies (CGT). Discover how developers can navigate challenges in patient access, regulatory requirements, and market entry. Understand the nuances between planning for allogeneic versus autologous therapies and effectively showcase therapy value amidst increasing competition. Gain insights on optimal timing for crafting your commercialization strategy and explore predictions for the CGT market in five years.